BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17124071)

  • 1. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular lymphocyte predominant Hodgkin lymphoma.
    Lee AI; LaCasce AS
    Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
    Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
    J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
    Goel A; Fan W; Patel AA; Devabhaktuni M; Grossbard ML
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):261-70. PubMed ID: 24650975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular lymphocyte-predominant Hodgkin lymphoma: current management strategies and evolving approaches to individualize treatment.
    Eichenauer DA; Hartmann S
    Expert Rev Hematol; 2023; 16(8):607-615. PubMed ID: 37337881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodular lymphocyte-predominant Hodgkin's lymphoma.
    Nogovà L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
    Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
    Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodular lymphocyte-predominant hodgkin lymphoma.
    Tsai HK; Mauch PM
    Semin Radiat Oncol; 2007 Jul; 17(3):184-9. PubMed ID: 17591565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Spinner MA; Varma G; Advani RH
    Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Fuchs M; von Tresckow B; Böll B; Behringer K; Diehl V; Eich HT; Borchmann P; Engert A
    J Clin Oncol; 2015 Sep; 33(26):2857-62. PubMed ID: 26240235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults.
    Huppmann AR; Nicolae A; Slack GW; Pittaluga S; Davies-Hill T; Ferry JA; Harris NL; Jaffe ES; Hasserjian RP
    Am J Surg Pathol; 2014 Mar; 38(3):316-24. PubMed ID: 24525501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
    Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma.
    Wang S; Medeiros LJ; Xu-Monette ZY; Zhang S; O'Malley DP; Orazi A; Zuo Z; Bueso-Ramos CE; Yin CC; Liu Z; Miranda RN; Young KH
    Ann Diagn Pathol; 2014 Aug; 18(4):203-9. PubMed ID: 24852241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern D.
    El Hussein S; Wang X; Fang H; Jelloul FZ; Wang W; Loghavi S; Vega F; Miranda RN; Muzzafar T; Manning JT; Khoury JD; Burack WR; Evans AG; Medeiros LJ
    Am J Surg Pathol; 2022 Sep; 46(9):1291-1297. PubMed ID: 35575765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.